TARSUS PHARMACEUTICALS, INC. Increase (Decrease) in Other Accrued Liabilities
TARSUS PHARMACEUTICALS, INC. (TARS) reported Increase (Decrease) in Other Accrued Liabilities of $28.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2026-06-30 was $13.30M, a 319.60% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2026-03-31 was $15.46M, a 52.06% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2025-06-30 was $3.17M.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2025-03-31 was $10.16M.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for fiscal 2025 was $45.39M, a 20.10% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for fiscal 2024 was $37.79M, a 334.25% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for fiscal 2023 was $8.70M.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|
| 2026-06-30 | $13.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $28.75M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $15.46M 10-Q · filed 2026-05-06 | ||
| 2025-12-31 | $45.39M 10-K · filed 2026-02-23 | ||
| 2025-06-30 | $3.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $13.33M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $10.16M 10-Q · filed 2026-05-06 | ||
| 2024-12-31 | $37.79M 10-K · filed 2026-02-23 | ||
| 2023-12-31 | $8.70M 10-K · filed 2026-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |